Acasti Pharma (ACST) News Today → The biggest energy story ever? (From Porter & Company) (Ad) Free ACST Stock Alerts $2.84 +0.06 (+2.16%) (As of 05/1/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAcasti Pharma (NASDAQ:ACST) Stock Price Passes Above 200 Day Moving Average of $2.74americanbankingnews.com - April 26 at 3:42 AMAcasti Pharma Inc. (NASDAQ:ACST) Short Interest Updateamericanbankingnews.com - April 26 at 1:30 AMAcasti Pharma Inc Class Amorningstar.com - December 14 at 2:27 PMAcasti to Participate in Upcoming San Francisco Investor Conferences in January 2024finance.yahoo.com - December 13 at 9:28 AMAcasti Announces Second Quarter 2024 Financial Results and Business Highlightsfinance.yahoo.com - November 13 at 8:21 AMOptimistic Outlook for Acasti Pharma’s GTX-104: Assessing Buy Rating and Potential Impact on Aneurysmal Subarachnoid Hemorrhage Treatmentmarkets.businessinsider.com - October 18 at 7:45 PMAcasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)finance.yahoo.com - October 4 at 10:40 AMAcasti announces $7.5M private placement equity fundingseekingalpha.com - September 27 at 1:55 PMAnalysts Are Bullish on Top Healthcare Stocks: Acasti Pharma (ACST), ImmunoPrecise Antibodies (IPA)markets.businessinsider.com - July 12 at 7:00 AMmarketbeat.com - July 10 at 10:28 AMAcasti Pharma: Reverse Stock Split To Become Effective July 10markets.businessinsider.com - July 7 at 8:48 AMAcasti Pharma Announces 1-for-6 Reverse Stock Splitfinance.yahoo.com - July 7 at 8:48 AMAcasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023finance.yahoo.com - July 5 at 1:57 PMRecap: Acasti Pharma Q4 Earningsmsn.com - June 23 at 9:34 AMWe're Hopeful That Acasti Pharma (NASDAQ:ACST) Will Use Its Cash Wiselyfinance.yahoo.com - May 10 at 9:21 AMAcasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025finance.yahoo.com - May 8 at 11:11 AMAcasti Announces Appointment of Prashant Kohli as CEOfinance.yahoo.com - April 4 at 9:53 AMAcasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the INDfinance.yahoo.com - April 4 at 9:53 AMWhen Will Acasti Pharma Inc. (NASDAQ:ACST) Turn A Profit?finance.yahoo.com - March 30 at 10:16 AMAcasti Pharma Inc. Announces the Resignation of a Directorfinance.yahoo.com - March 30 at 10:16 AMAcasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchangefinance.yahoo.com - March 13 at 8:09 AMAcasti Pharma's Earnings Outlookmsn.com - February 13 at 10:44 AMAcasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023finance.yahoo.com - February 7 at 9:52 AMAcasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rulefinance.yahoo.com - January 25 at 12:31 PMAcasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcastfinance.yahoo.com - January 17 at 9:46 AMAcasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measuresfinance.yahoo.com - January 5 at 10:03 AMH.C. Wainwright Keeps Their Buy Rating on Acasti Pharma (ACST)markets.businessinsider.com - December 29 at 8:20 AMAcasti Pharma Inc. (NASDAQ:ACST) Q2 2023 Earnings Call Transcriptfinance.yahoo.com - December 29 at 8:20 AMAcasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasiafinance.yahoo.com - December 28 at 8:39 AMAcasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)finance.yahoo.com - December 22 at 12:23 PMAcasti Pharma Reports Second Quarter 2023 Operational Resultsfinancialpost.com - November 14 at 7:14 AMAcasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022finance.yahoo.com - November 8 at 9:17 AMAcasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholdersfinance.yahoo.com - September 29 at 11:41 AMAcasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day Podcastfinance.yahoo.com - September 21 at 12:05 PMAcasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasiafinance.yahoo.com - September 13 at 8:27 AMAcasti Pharma: Top 10 Undervalued Healthcare Stocks on TSX Venture Exchange (ACST)theglobeandmail.com - September 10 at 9:11 PMEdited Transcript of ACST.V earnings conference call or presentation 11-Aug-22 5:00pm GMTfinance.yahoo.com - August 25 at 9:22 PMAcasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q1 2023 Results - Earnings Call Transcriptseekingalpha.com - August 11 at 5:57 PMAcasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022finance.yahoo.com - August 2 at 5:57 PMAcasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company's Drug Candidate for the Treatment of Postherpetic Neuralgiastockhouse.com - July 29 at 4:48 AMAcasti Pharma Reports Fiscal Year 2022 Operational Resultsfinance.yahoo.com - June 21 at 8:23 AMAcasti Pharma Schedules Fiscal Year 2022 Business Update Conference Callfinance.yahoo.com - June 16 at 5:47 PMAcasti gets patents related to brain hemorrhage drug GTX-104, pain therapy GTX-101seekingalpha.com - June 14 at 10:47 AMAcasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101finance.yahoo.com - June 14 at 10:47 AMAcasti Pharma's IV Hemorrhage Drug Candidate At Par With Oral Nimodipinefinance.yahoo.com - May 18 at 3:32 PMAcasti says pharmacokinetic trial for lead asset met all study goalsseekingalpha.com - May 18 at 10:00 AMAcasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpointsfinance.yahoo.com - May 18 at 10:00 AMUpdate: Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 18thstockhouse.com - May 17 at 1:58 PMAcasti Pharma Inc.: Update: Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 18thfinanznachrichten.de - May 16 at 3:59 PMUpdate: Acasti Pharma CEO to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 18thfinance.yahoo.com - May 16 at 3:59 PM Get Acasti Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s last act as President (Ad)You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. For the full story, click here. ACST Media Mentions By Week ACST Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACST News Sentiment▼-0.010.35▲Average Medical News Sentiment ACST News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACST Articles This Week▼30▲ACST Articles Average Week Get Acasti Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: FBRX News SLGL News QLI News DRRX News ITRM News EYEN News LPCN News VAXX News SPRB News LEXX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACST) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyAI “wealth window” is closing June 25thParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acasti Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
